Paul B. Watkins

Paul B. Watkins
Born1953 (age 72–73)
Scotia, New York, U.S.
EducationCornell University (BA)
Cornell Medical College (MD)
Known forCYP3A4 characterization; grapefruit juice–drug interaction; DILIsym software
Scientific career
FieldsHepatology; Pharmacology; Toxicology
WorkplacesUniversity of North Carolina at Chapel Hill

Paul Brent Watkins (born 1953) is an American physician, hepatologist, and pharmacologist. He is the Howard Q. Ferguson Distinguished Professor at the University of North Carolina Eshelman School of Pharmacy and Professor of Medicine and Public Health at UNC Chapel Hill. His research has focused on drug metabolism, drug-induced liver injury (DILI), and computational toxicology.[1]

He is a Fellow of American College of Physicians, American Gastroenterological Association, and American Association for the Study of Liver Diseases.[1]

Early life and education

Watkins was raised in Scotia, New York, and attended Burnt Hills–Ballston Lake Senior High School. He received a B.A. in Physical Chemistry from Cornell University in 1975 and an M.D. from Weill Cornell Medical College in 1979.[2]

He completed his internship and residency in internal medicine at The New York Hospital–Cornell Medical Center (1979–1982). He then served as a physician at the Khao-I-Dang Cambodian refugee camp in Thailand (April–July 1982), followed by a fellowship in gastroenterology and hepatology at the Medical College of Virginia (1982–1984), where he also trained as an NIH-funded research fellow in environmental medicine and clinical toxicology.[1]

Academic career

Watkins joined the faculty of the Medical College of Virginia as an instructor and later assistant professor of medicine (1984–1986). He subsequently moved to the University of Michigan, where he rose to full professor of medicine and served as director of the General Clinical Research Center (1991–1999), and was appointed professor of pharmacology in 1998.[3]

In 1999, he joined UNC Chapel Hill as the Verne S. Caviness Distinguished Professor of Medicine and Professor of Pharmacy, and director of the General Clinical Research Center. He became the inaugural director of the Hamner-UNC Institute for Drug Safety Sciences (2008–2023) and was named the Howard Q. Ferguson Distinguished Professor of Pharmacy in 2016.[4] He also holds an appointment as Professor of Public Health. Since 2023, he has served as co-director and contact principal investigator for the Triangle Center of Excellence in Regulatory Science and Innovation (CESI), an FDA-funded collaborative centre involving UNC, Duke University, North Carolina State University, and North Carolina Central University.[5][6]

Research

CYP3A4 and drug metabolism

Watkins was lead author on a 1985 paper in Proceedings of the National Academy of Sciences that characterised an inducible form of cytochrome P450 in human liver, later designated CYP3A4, an enzyme now understood to be involved in the metabolism of a large proportion of clinically used drugs.[7]

A 1987 paper in the Journal of Clinical Investigation by his group reported expression of CYP3A4 in the wall of the small intestine, indicating that this enzyme contributes to limiting the oral absorption of certain drugs before they reach systemic circulation.[8]

He developed and patented the 14C-erythromycin breath test (ERMBT) as a non-invasive measure of hepatic CYP3A4 activity.[9][10][11]

Watkins was senior author on a 1991 Lancet study conducted during human liver transplantation that demonstrated substantial first-pass metabolism of ciclosporin in the gut.[12]

Grapefruit juice–drug interaction

Watkins's laboratory identified the furanocoumarin 6′,7′-dihydroxybergamottin (DHB) as a principal constituent of grapefruit juice responsible for its interactions with certain medications.[13] A 1997 Journal of Clinical Investigation study described the mechanism by which grapefruit juice decreases intestinal CYP3A protein expression, thereby increasing the oral bioavailability of affected drugs.[14]

Drug-induced liver injury

Watkins was senior author on a 2023 Gastroenterology paper that identified a genetic risk score, incorporating reduced ERAP2 expression and a novel HLA allele associated with susceptibility to drug-induced liver injury from amoxicillin-clavulanate.[15][16]

A 2006 JAMA study reported elevations in serum alanine aminotransferase (ALT) in healthy subjects receiving four grams of acetaminophen daily.[17]

Honours and awards

Selected publications

References

  1. 1 2 3 "Paul B. Watkins, MD". Eshelman School of Pharmacy. Retrieved June 16, 2026.
  2. ↑ "Paul Watkins". UNC Lineberger Comprehensive Cancer Center. Retrieved June 16, 2026.
  3. ↑ "Paul Watkins, MD". UNC Gillings School of Global Public Health.
  4. ↑ "Experts will review ongoing efforts to curb drug-induced liver injury". DDW News. May 7, 2017. Retrieved June 16, 2026.
  5. ↑ catlong (July 11, 2023). "UNC-Chapel Hill and Duke University to be awarded up to $50 million from the FDA for new research center". UNC News. Retrieved June 16, 2026.
  6. ↑ "Duke, UNC-Chapel Hill Awarded up to $50 Million from the FDA for New Research Center". Duke Health. July 11, 2023.
  7. ↑ Watkins, P B; Wrighton, S A; Maurel, P; Schuetz, E G; Mendez-Picon, G; Parker, G A; Guzelian, P S (1985). "Identification of an inducible form of cytochrome P-450 in human liver". Proceedings of the National Academy of Sciences. 82 (18): 6310–6314. Bibcode:1985PNAS...82.6310W. doi:10.1073/pnas.82.18.6310. ISSN 0027-8424. PMC 391043. PMID 3898085.
  8. ↑ Watkins, P B; Wrighton, S A; Schuetz, E G; Molowa, D T; Guzelian, P S (October 1, 1987). "Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man". Journal of Clinical Investigation. 80 (4): 1029–1036. doi:10.1172/JCI113156. ISSN 0021-9738. PMC 442342. PMID 3654968.
  9. ↑ Watkins, P B; Murray, S A; Winkelman, L G; Heuman, D M; Wrighton, S A; Guzelian, P S (February 1, 1989). "Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients". Journal of Clinical Investigation. 83 (2): 688–697. doi:10.1172/JCI113933. ISSN 0021-9738. PMC 303730. PMID 2913056.
  10. ↑ Watkins, Paul B. (1996). "Erythromycin Breath Test and Clinical Transplantation". Therapeutic Drug Monitoring. 18 (4): 368–371. doi:10.1097/00007691-199608000-00009. ISSN 0163-4356. PMID 8857552.
  11. ↑ Lown, Kenneth S.; Thummel, Kenneth E.; Benedict, Patrick E.; Shen, Danny D.; Turgeon, Danielle K.; Berent, Stanley; Watkins, Paul B. (1995). "The erythromycin breath test predicts the clearance of midazolam*". Clinical Pharmacology & Therapeutics. 57 (1): 16–24. doi:10.1016/0009-9236(95)90261-9. hdl:2027.42/109946. ISSN 0009-9236. PMID 7828377.
  12. ↑ Kolars, J.C; Watkins, P.B; Merion, R.M; Awni, W.M (1991). "First-pass metabolism of cyclosporin by the gut". The Lancet. 338 (8781): 1488–1490. doi:10.1016/0140-6736(91)92302-I. hdl:2027.42/28982. PMID 1683920.
  13. ↑ Schmiedlin-Ren, P.; Edwards, D. J.; Fitzsimmons, M. E.; He, K.; Lown, K. S.; Woster, P. M.; Rahman, A.; Thummel, K. E.; Fisher, J. M.; Hollenberg, P. F.; Watkins, P. B. (1997). "Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins". Drug Metabolism and Disposition: The Biological Fate of Chemicals. 25 (11): 1228–1233. ISSN 0090-9556. PMID 9351897.
  14. ↑ Di Cola, G; Cool, M H; Accili, D (May 15, 1997). "Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors". Journal of Clinical Investigation. 99 (10): 2538–2544. doi:10.1172/JCI119438. ISSN 0021-9738. PMC 508095. PMID 9153298.
  15. ↑ Krug, Julia; Rodrian, Gabriele; Petter, Katja; Yang, Hai; Khoziainova, Svetlana; Guo, Wei; Bénard, Alan; Merkel, Susanne; Gellert, Susan; Maschauer, Simone; Spermann, Monika; Waldner, Maximilian; Bailey, Peter; Pilarsky, Christian; Liebl, Andrea (2023). "N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy". Gastroenterology. 164 (3): 392–406.e5. doi:10.1053/j.gastro.2022.11.018. PMC 10009756. PMID 36402190.
  16. ↑ "DILIN: Prospective (DILIN Pro)". NIDDK Central Repository. National Institutes of Health.
  17. ↑ Watkins, Paul B.; Kaplowitz, Neil; Slattery, John T.; Colonese, Connie R.; Colucci, Salvatore V.; Stewart, Paul W.; Harris, Stephen C. (July 5, 2006). "Aminotransferase Elevations in Healthy Adults Receiving 4 Grams of Acetaminophen Daily: A Randomized Controlled Trial". JAMA. 296 (1): 87–93. doi:10.1001/jama.296.1.87. ISSN 0098-7484. PMID 16820551.